MedTrace Logo

MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation

NCT02091973 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-03-19

No results posted yet for this study

Summary

The calcineurin inhibitor drugs including cyclosporin and tacrolimus are well-known as nephrotoxicity. However, these drugs are essential for kidney transplant especially in high immunological risks. To date, however, there is an alternative regimen by using of everolimus-based which showing less toxicity than tacrolimus-based regimen by its mechanisms. Of note, this study aims to evaluate the toxicity by using microRNA profiles detection between everolimus-based and tacrolimus-based immunosuppressive regimen in kidney transplantation.

Conditions

  • microRNA Profiles

Interventions

DRUG

Everolimus

Everolimus dosing to target tough level 6-10 mg/ml

DRUG

Tacrolimus

Tacrolimus dosing to target tough level 5-10 ng/ml

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Wiwat Chancharoenthana, MD, Msc. · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02091973 on ClinicalTrials.gov